Expressing support for the designation of September 2026 as "National Prostate Cancer Awareness Month".
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This resolution expresses support for designating September 2026 as National Prostate Cancer Awareness Month. It highlights the significant impact of prostate cancer in the United States, including its high incidence and mortality rates, particularly among African-American men. The resolution encourages increased awareness, research, and improved access to healthcare for prostate cancer detection and treatment, aiming to save lives and support families.
Key provisions
- Designates September 2026 as National Prostate Cancer Awareness Month.
- Calls for increased awareness of prostate cancer screening and treatment.
- Encourages research into improved screening, treatment, and causes of prostate cancer.
- Promotes the development of a cure for prostate cancer.
- Supports efforts to improve access to quality healthcare for prostate cancer patients.
- Asks for the promotion of awareness of prostate cancer.
- Requests that people take an active role in the fight against prostate cancer.
- Encourages the observation of National Prostate Cancer Awareness Month with ceremonies and activities.
Who is affected
- Men in the United States
- Families of men with prostate cancer
- African-American men
- Veterans
Notable changes
- The resolution focuses on raising awareness and promoting preventative measures for prostate cancer.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
5 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours